Related Experiment Video

Updated: May 18, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

A drug safety evaluation of everolimus in kidney transplantation

Hallvard Holdaas1, Karsten Midtvedt, Anders Åsberg

  • 1Oslo University Hospital, Department of Transplant Medicine, Section of Nephrology, Rikshospitalet, Postbox 4950 Nydalen, N-0424 Oslo, Norway. hallvard.holdaas@rikshospitalet.no

Expert Opinion on Drug Safety
|September 8, 2012
PubMed
Abstract

Insights

Everolimus, an mTOR inhibitor, improves kidney transplant outcomes by enhancing graft function and offering a better safety profile than calcineurin inhibitors. It presents a manageable adverse event profile for long-term use.

Area of Science:

  • Organ transplantation and immunosuppression.
  • Pharmacology of mTOR inhibitors.

Background:

  • Calcineurin inhibitors (CNIs) improve short-term transplant survival but not long-term outcomes.
  • CNIs are linked to graft fibrosis, cardiovascular risks, and malignancies.
  • Everolimus (mTOR inhibitor) lacks graft fibrosis association and offers a better cardiovascular profile.

Purpose of the Study:

  • To review the mechanism, pharmacokinetics, pharmacodynamics, and clinical data of everolimus.
  • To focus on the safety and efficacy of everolimus in organ transplantation.

Main Methods:

  • Literature review of pivotal clinical studies on everolimus.
  • Summary of everolimus's pharmacological properties and drug interactions.

Main Results:

  • Everolimus demonstrates efficacy in improving graft function in kidney transplant recipients.
  • Adverse events associated with everolimus are typically transient and manageable.
  • Everolimus shows potential in cancer prevention and treatment.

Conclusions:

  • Everolimus is effective for selected kidney transplant patients, improving graft function.
  • The safety profile of everolimus is favorable, with manageable adverse events.
  • Everolimus is a promising agent for de novo and maintenance immunosuppression in kidney transplantation.

More Related Videos

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...